Also to high light from half year report , "We are continuing to...

Also to high light from half year report ,
"We are continuing to build and expand our clinical trial programme in order to establish an optimal path to product registration and to explore possible new indications for CAVATAK. We see this work as critical to strengthening partnering discussions and generating shareholder value. Strong news flow will continue in 2017 as we report on the clinical progress of CAVATAK as a potential new treatment in the fast-growing field of cancer immunotherapy."
1-5 April more data to come .